SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of

-PRA023, an anti-TL1A mAb, on track to initiate Phase 2 study for Ulcerative Colitis and Phase 2a study for Crohn’s Disease in 3Q 2021- -Launched Prometheus Enroll360™, a global patient recruitment platform for accelerated patient enrollment in future biomarker-guided clinical trials- -Successful

SAN DIEGO, March 16, 2021 / PRNewswire / -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory

SAN DIEGO, March 11, 2021 / PRNewswire / -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory

SAN DIEGO, March 4, 2021 / PRNewswire / -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory

- PRA023 is a TL1A antibody targeting both inflammation and fibrosis in patients with ulcerative colitis and Crohn's disease - - PRA023 is being developed to be used in combination with a companion diagnostic to identify responders in novel precision medicine approach - SAN DIEGO, March 3, 2021 /

SAN DIEGO, Feb. 16, 2021 / PRNewswire / -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory

- PRA023 is a TL1A antibody targeting both inflammation and fibrosis in patients with ulcerative colitis and Crohn's disease - - PRA023 is being developed to be used in combination with a companion diagnostic to identify responders in novel precision medicine approach - SAN DIEGO, Dec.

- New investors include Eventide, RTW, Perceptive Advisors, Cormorant Capital, Cowen Healthcare Investments and Point72 - -Proceeds to accelerate clinical development of PRA023, a potential best in class TL1A antibody for IBD, and expansion of Promtheus' 360 platform - SAN DIEGO, Nov.

SAN DIEGO, September 29, 2020 / PRNewswire / — Prometheus Biosciences, Inc., (“Prometheus”) a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of